Cantor Fitzgerald Raises Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities researchers at Cantor Fitzgerald increased their FY2025 earnings estimates for shares of Gossamer Bio in a research note issued on Monday, March 24th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will earn ($0.70) per share for the year, up from their prior forecast of ($0.72). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Several other research analysts have also recently issued reports on GOSS. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a report on Friday, March 14th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, March 18th.

Gossamer Bio Stock Performance

Shares of Gossamer Bio stock opened at $1.16 on Wednesday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock’s fifty day moving average price is $1.19 and its 200-day moving average price is $0.99. The firm has a market cap of $263.58 million, a P/E ratio of -3.63 and a beta of 1.86. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The firm had revenue of $9.38 million during the quarter, compared to the consensus estimate of $7.02 million.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors have recently added to or reduced their stakes in the stock. Octagon Capital Advisors LP raised its holdings in Gossamer Bio by 99.7% in the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock worth $16,599,000 after purchasing an additional 9,162,117 shares in the last quarter. Alyeska Investment Group L.P. raised its stake in shares of Gossamer Bio by 52.7% during the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock worth $7,968,000 after acquiring an additional 3,041,058 shares in the last quarter. Monaco Asset Management SAM lifted its position in Gossamer Bio by 39.5% during the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after acquiring an additional 1,520,721 shares during the last quarter. Allostery Investments LP acquired a new stake in Gossamer Bio in the fourth quarter valued at approximately $555,000. Finally, Silverarc Capital Management LLC boosted its stake in Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock valued at $5,583,000 after acquiring an additional 526,495 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.